|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:ceo
|
gptkb:Stéphane_Bancel
|
|
gptkbp:clinical_phase
|
Phase 3 trials
|
|
gptkbp:clinical_trial
|
COVID-19 vaccine trials
multiple ongoing
|
|
gptkbp:collaboration
|
gptkb:Merck
gptkb:GSK
gptkb:Astra_Zeneca
gptkb:Vertex_Pharmaceuticals
gptkb:Operation_Warp_Speed
|
|
gptkbp:developed_by
|
gptkb:vaccine
|
|
gptkbp:employees
|
over 1,800
|
|
gptkbp:focus
|
m RNA therapeutics
|
|
gptkbp:focuses_on
|
m RNA technology
|
|
gptkbp:founded
|
gptkb:2010
|
|
gptkbp:founded_by
|
gptkb:Derrick_Rossi
gptkb:Robert_Langer
gptkb:Noubar_Afeyan
Tal Zaks
|
|
gptkbp:founder
|
gptkb:Noubar_Afeyan
|
|
gptkbp:has_research_center
|
gptkb:Cambridge,_Massachusetts
gptkb:Canada
gptkb:Switzerland
gptkb:United_Kingdom
gptkb:Norwood,_Massachusetts
|
|
gptkbp:headcount
|
over 1,800 employees (2021)
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Moderna
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:ipo
|
gptkb:2018
|
|
gptkbp:is_vulnerable_to
|
gptkb:Spikevax
gptkb:m_RNA-1273
global
global health initiatives
global vaccination efforts
94.1% against symptomatic COVID-19
collaboration with governments
reduced hospitalization rates
development of personalized medicine
Emergency Use Authorization (EUA)
economic recovery support
contributed to herd immunity
reduced severe disease
decreased transmission rates
increased public health safety
partnership with NGOs
advancements in vaccine technology
increased investment in biotech
influence on future vaccine development
potential for other diseases
public awareness of m RNA technology
research funding for m RNA technology
research on cancer vaccines
-20° C for up to 6 months
|
|
gptkbp:market_cap
|
over $100 billion
approximately $50 billion (2021)
|
|
gptkbp:notable_products
|
gptkb:m_RNA-1273
gptkb:vaccine
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Lonza_Group
gptkb:National_Institutes_of_Health
gptkb:Merck_&_Co.
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:regulatory_compliance
|
Emergency Use Authorization
|
|
gptkbp:research_focus
|
infectious diseases
|
|
gptkbp:revenue
|
$17.7 billion (2021)
$803 million (2020)
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
MRNA
|
|
gptkbp:technology
|
m RNA technology
|
|
gptkbp:uses_technology
|
messenger RNA (m RNA)
|
|
gptkbp:vaccine_administration
|
intramuscular injection
|
|
gptkbp:vaccine_age_approval
|
12 years and older
|
|
gptkbp:vaccine_approval
|
full approval by FDA
|
|
gptkbp:vaccine_booster
|
available
third dose
|
|
gptkbp:vaccine_distribution
|
global distribution
|
|
gptkbp:vaccine_doses
|
two doses
|
|
gptkbp:vaccine_efficacy
|
94.1% for COVID-19
|
|
gptkbp:vaccine_side_effects
|
fatigue
headache
muscle pain
nausea
fever
joint pain
chills
|
|
gptkbp:vaccine_storage
|
-20° C for 6 months
|
|
gptkbp:vaccine_type
|
gptkb:vaccine
|
|
gptkbp:bfsParent
|
gptkb:COVID-19_Pandemic
gptkb:Pfizer
gptkb:Pfizer_Inc.
gptkb:COVID-19
gptkb:Vertex_Pharmaceuticals
gptkb:COVID-19_pandemic
gptkb:Cure_Vac
|
|
gptkbp:bfsLayer
|
4
|